Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 77Lymphoma 62Melanoma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 42Leukemia 41Lymphoma, Non-Hodgkin 31Burkitt Lymphoma 30Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 26Neuroblastoma 24Lymphoma, Follicular 23Neoplasm Metastasis 21Leukemia, Myeloid, Acute 19Sarcoma 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms, Plasma Cell 17Lymphoma, Mantle-Cell 17Skin Neoplasms 16Ovarian Neoplasms 14Kidney Neoplasms 14Neoplasms 13Hodgkin Disease 13Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Central Nervous System Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Large-Cell, Anaplastic 10

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anatomic Stage II Breast Cancer AJCC v8 × Cyclophosphamide × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡